**GENERAL      SERVICES AGREEMENT**

**Recitals:**

**Agreement:**

| 1.0 | **Services                to be Provided.**The                services to be performed hereunder (the “Services”) shall be                specified in the Scope of Work attached hereto as Attachment 1. Any                responsibilities not                specifically transferred in this Agreement shall remain the responsibility                of Sponsor. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.0 | **Payment                of Fees and Expenses.**Sponsor                will pay Quintiles for fees, expenses and pass-through                costs in accordance with the budget and payment schedule attached                hereto                as Attachment                2. Based on the estimated cash flow of the Project, Sponsor agrees                that a                prepayment                may be needed for Quintiles to maintain cash neutrality over the                term of                the Project                taking into account the payment terms agreed to between the parties.                Quintiles will invoice                Sponsor for its fees in accordance with the payment schedule and                monthly                for expenses                and pass-through costs incurred in performing the Services. Expenses                and                pass-through                costs will be supported by a summary sheet. With the exception of                any                prepayment or advances and investigator invoices, which are due and                payable upon receipt, all other invoice payments shall be made to                Quintiles within thirty (30) days of receipt. If any portion of an                invoice                is disputed, then Sponsor shall pay the undisputed amounts as set                forth in                the preceding                sentence and the parties shall use good faith efforts to reconcile                the                disputed amount                as soon as practicable. Sponsor shall pay Quintiles interest in an                amount                equal to four percent (4%) above the base interest rate established                by                Fortis Bank Limited per month of all undisputed amounts owing hereunder                and not paid when due (or the maximum lesser amount                permitted by applicable law). In the event that taxes or duties,                of                whatever nature, are                required to be withheld on payments made pursuant to this Agreement                by any                state, federal, provincial or foreign government, including, but                not                limited to, Value Added Tax, |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| Payable                to: | **Quintiles                Limited**Fortis                Bank23                Camomile StreetLondonEC3A                7PPEngland |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------|
|                       |                                                                                                                                |
| Sort                Code:  | 40-52-62                                                                                                                            |
| Account Number:       | 21810137                                                                                                                            |
| Swift:                     | GEBAGB22                                                                                                                            |
| IBAN:                      | GB19GEBA40526221810137                                                                                                              |

| 3.0 | **Term.**This                Agreement shall commence on the date it has been signed by all parties                and                shall continue until the Services are completed or until terminated                by                either party in accordance                with Section 17 below. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.0 | **Change                Orders.**Any                change in the details of this Agreement or the assumptions upon                which                this Agreement is based (including, but not limited to, changes in                an                agreed starting                date for the Project or suspension of the Project by Sponsor) may                require                changes in                the budget and/or time lines, and shall require a written amendment                to the                Agreement (a                “Change Order”). Each Change Order shall detail the requested changes to                the applicable                task, responsibility, duty, budget, time line or other matter. The                Change                Order will become effective upon the execution of the Change Order                by both                parties, and Quintiles will be given a reasonable period of time                within                which to implement the changes. Both parties agree to act in good                faith                and promptly when considering a Change Order requested by the other                party.                Without limiting the foregoing, Sponsor agrees that it will not                unreasonably withhold approval of a Change Order, Either party reserves                the right                to postpone effecting material changes in the Project's scope until                such                time as the parties                agree to and execute the corresponding Change Order. For any Change                Order                that                affects the scope of the regulatory obligations that have been transferred                to Quintiles, Quintiles                and Sponsor shall execute a corresponding amendment to the Transfer                of                Obligations Form. Sponsor shall file such amendment where appropriate,                or                as required by                law or regulation. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.0 | **Confidentiality.**It                is understood that during the course of this Agreement, Quintiles                and its                employees may be exposed to data and information that are confidential                and                proprietary                to Sponsor. It is understood that project results are Confidential                and                proprietary to the Sponsor and all such data and information (hereinafter                is collectively termed                “Sponsor Confidential Information”) written or verbal, tangible or                intangible, made                available, disclosed, or otherwise made known to Quintiles and its                employees as a result of Services under this Agreement shall be considered                confidential and shall be considered the sole property of Sponsor.                All                information regarding Quintiles' operations, methods, and pricing                and all                Quintiles' Property (as defined in Section 6.0 below), disclosed                by                Quintiles to Sponsor in connection with this Agreement is proprietary,                confidential information belonging to Quintiles (the “Quintiles                Confidential Information”, and together with the Sponsor Confidential                Information, the “Confidential Information”). The Confidential Information                shall be used by the receiving party and its employees only for purposes                of performing the receiving party's obligations hereunder. Each party                agrees that it will not reveal, publish or otherwise disclose the                Confidential Information of the other party to any third party without                the                prior written consent of the disclosing party. Each party agrees                that it                will not disclose the terms of this Agreement to any third party                without                the written consent of the other party, which shall not unreasonably                be                withheld. These obligations of confidentiality and nondisclosure                shall                remain in effect for a period of ten (10) years after the completion                or                termination of the Agreement. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 6.0 | **Ownership                and Inventions.**All                data and information generated or derived by Quintiles as the result                of                Services performed by Quintiles under this Agreement shall be and                remain                the exclusive property of Sponsor. Any inventions that may evolve                from the                data and information described above or as the result of Services                performed by Quintiles under this Agreement shall belong to Sponsor                and                Quintiles agrees to assign its rights in all such inventions and/or                related patents to Sponsor. Notwithstanding the foregoing, Sponsor                acknowledges that Quintiles possesses certain inventions, processes,                know-how, trade secrets, improvements, other intellectual properties                and                other assets, including but not limited to analytical methods, procedures                and techniques, procedure manuals, personnel data, financial information,                computer technical expertise and software, which have been independently                developed by Quintiles and which relate to its business or operations                (collectively “Quintiles' Property”). Sponsor and Quintiles agree that any                Quintiles' Property or improvements thereto which are used, improved,                modified or developed by Quintiles under or during the term of this                Agreement are the sole and exclusive property of                Quintiles. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.0 | **Records                and Materials.**At                the completion of the Services by Quintiles, all materials, information                and all other data owned by Sponsor, regardless of the method of                storage                or retrieval, shall be delivered to Sponsor in such form as is then                currently in the possession of Quintiles. Alternatively, at Sponsor's                written request, such materials and data may be retained by Quintiles                for                Sponsor for an agreed-upon time period, or disposed of pursuant to                the                written directions of Sponsor. Sponsor shall pay the costs associated                with                any of the above options and shall pay a to-be-determined fee for                storage                by Quintiles of records and materials after completion or termination                of                the Services. Quintiles, however, reserves the right to retain, at                its own                cost and subject to the confidentiality provisions herein, one copy                of all                materials that may be needed to satisfy regulatory requirements or                to                resolve disputes regarding the Services. Nothing in this Agreement                shall                be construed to transfer from Sponsor to Quintiles any FDA or regulatory                record-keeping requirements unless such transfer is specifically                provided                for in the applicable Transfer of Obligations                Form. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 8.0 | **Independent                Contractor Relationship.**For                the purposes of this Agreement, the parties hereto are independent                contractors and nothing contained in this Agreement shall be construed                to                place them in the relationship of partners, principal and agent,                employer/employee or joint venturers. Neither party shall have the                power                or right to bind or obligate the other party, and neither party shall                hold                itself out as having such authority. If, however, Sponsor desires                to                conduct clinical trials in one or more countries that require a local                sponsor or representative, and Sponsor requests that Quintiles or                its                affiliates serve as its agent for that purpose, then Quintiles may                serve                as Sponsor's agent for the purpose of fulfilling local sponsor or                representative duties. Sponsor shall pay Quintiles for such local                representative services at Quintiles' standard daily rates, unless                otherwise specified in the attached                Budget. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.0 | **a)                Regulatory Compliance.**Quintiles                agrees that its Services will be conducted in compliance                with all applicable laws, rules and regulations and with the standard                of                care customary in the contract research organization industry (excluding                21 CFR Part 11). Quintiles shall process all personal data in accordance                with this Agreement or as otherwise instructed by Sponsor or its                affiliates in compliance with the EU Data Protection Directive 95/46/EC                and any applicable national legislation enacted thereunder (“Data                Protection Legislation”). Sponsor represents and affirms to Quintiles that                Sponsor has complied with, and will continue to comply with its                obligations under the Data Protection Legislation. Quintiles' standard                operating procedures will be used in performance of the Services,                unless                otherwise specifically stated in the Scope of Work. Quintiles certifies                that it has not been debarred under the Generic Drug Enforcement                Act and                that it will not knowingly employ any person or entity that has been                so                debarred to perform any Services under this Agreement. Sponsor represents                and certifies that it will not require Quintiles to perform any                assignments or tasks in a manner that would violate any applicable                law or                regulation. Sponsor further represents that it will cooperate with                Quintiles in taking any actions that Quintiles reasonably believes                are                necessary to comply with the regulatory obligations that have been                transferred to Quintiles.  **b)                Inspections and Audits.**Each                party acknowledges that the other party may respond independently                to any                regulatory correspondence or inquiry in which such party or its affiliates                is named. Each party, however, shall not respond on behalf of the                other                party to any such regulatory correspondence or inquiry, unless otherwise                agreed by the parties, and shall notify the other party promptly                of any                FDA or other governmental or regulatory inspection or inquiry concerning                the Services. During any such inspection or inquiry, the parties                agree to                make reasonable efforts to disclose only the information required                to be                disclosed.                During the term of this Agreement, Quintiles will permit Sponsor's                representatives                (unless such representatives are competitors of Quintiles) to examine                or                audit the work performed hereunder and the facilities at which the                work is                conducted upon reasonable advance notice during regular business                hours to                determine that the Services                are being conducted in accordance with the agreed task and that the                facilities are adequate.                Sponsor agrees that it shall not disclose to any third party any                information ascertained by Sponsor in connection with any such audit                or                examination, except to the extent                required by law or regulation. Sponsor shall reimburse Quintiles                for its                time and expenses                (including reasonable attorney fees and the costs of responding to                findings) associated with any inspection, audit or investigation                relating                to the Services (“Inspection”)                instigated by Sponsor or by a governmental authority, unless such                Inspection                finds that Quintiles breached this Agreement or any applicable law                or                regulation. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 10.0 | **Relationship                with Investigators.**If Quintiles will be obligated to contract                with investigators or investigative sites (collectively, “Investigators”)                then Quintiles will use its standard Clinical Trial Agreement (“Global                CTA”) form, a copy of which is attached hereto as Attachment 3, along                with                certain local CTA forms (“Local CTAs”) that have developed for use in                certain countries based on local requirements with the benefit of                local                legal advice, which have been prepared in local language and English                language where applicable. Any applicable Local CTAs will be made                available for inspection by the Sponsor upon request. If the Global                CTA                form or a Local CTA is updated, Quintiles will use its then current                Global                CTA form (or Local CTA as appropriate) as of the time of the agreement.                If                Sponsor insists that any CTA form other than the Global CTA and Local                CTAs                be used, then Sponsor shall pay all translation costs and additional                negotiation time may be required. If an Investigator insists upon                any                material changes to any provisions that directly affect Sponsor,                then                Quintiles shall submit the proposed material change to Sponsor, and                Sponsor shall review, comment on and/or approve such proposed changes                within five (5) working days. If the Global CTA form (or Local CTA,                where                applicable), or any changes approved by Sponsor, differ from the                terms of                this Agreement (including, but not limited to, provisions allowing                an                Investigator to publish results or data that Quintiles is prohibited                from                revealing), then Quintiles shall have no liability for any such approved                provisions or changes. Unless otherwise stated in the attached Budget,                the                time incurred by Quintiles in negotiating CTA changes proposed by                sites                shall be billed at Quintiles' Standard Rates. The parties acknowledge                and                agree that Investigators shall not be considered the employees, agents,                or                subcontractors of Quintiles or Sponsor and that Investigators shall                exercise their own independent medical judgment. Quintiles'                responsibilities with respect to Investigators shall be limited to                those                responsibilities specifically set forth in this                Agreement. |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
|   | If              Quintiles will be paying Investigators on behalf of Sponsor, the parties              will agree in the attached Payment Schedule as to a schedule of amounts              to              be paid to Investigators. Sponsor acknowledges and agrees Quintiles              will              only pay Investigators from advances or pre-payments received from              Sponsor              for Investigators' services, and that Quintiles will not make payments              to              Investigators prior to receipt of sufficient funds from Sponsor. Sponsor              acknowledges and agrees that Quintiles will not be responsible for              delays              in a study or Project to the extent that such delays are caused by              Sponsor's failure to make adequate pre-payment for Investigators'              services. Sponsor further acknowledges and agrees that payments for              Investigators' services are pass-through payments to third parties              and are              separate from payments for Quintiles' Services. Sponsor agrees that              it              will not withhold Investigator payments except to the extent that it              has              reasonable questions about the services performed by a particular              Investigator. For the avoidance of doubt, nothing contained in this              clause, or elsewhere in this Agreement, is intended to confer any right              or              benefit on any third party including, but not limited to, any              Investigator, whether under the provisions of the Contracts (Rights              of              Third Parties) Act 1999 or otherwise. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 11.0 | **Third                Party Indemnifications and Agreements.**If                any investigative sites or any other third parties, including, but                not                limited to, Data Safety Monitoring Boards, independent laboratories,                Advisory Boards, or End Point Adjudication Committees (collectively,                “Third Parties”), request an indemnification for loss or damage caused by                the sponsor's Project, then Sponsor shall be responsible for providing                such indemnification directly to the Third Party, on terms and conditions                to be agreed between Sponsor and the Third Party. If Sponsor requests                Quintiles' assistance in negotiating the terms of such indemnities,                Quintiles shall provide such negotiation services at its standard                daily                rates, unless otherwise agreed in the attached Budget. Quintiles                shall not                sign such indemnifications on Sponsor's behalf unless Sponsor has                expressly authorized Quintiles to act as its agent for such purpose                or has                given Quintiles a written power of attorney to sign such indemnifications.                In countries in which local laws or local ethics committees require                that a                local company must sign such indemnifications and Sponsor has no                local                presence, Quintiles will sign such indemnities only if the parties                have                entered into an agreement regarding local representative duties containing                the terms attached hereto as Attachment B, either as a part of this                Agreement or as a separately signed                agreement. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.0 | **Conflict                of Agreements.**Quintiles                represents to Sponsor that it is not a party to any agreement which                would                prevent it from fulfilling its obligations under this Agreement and                that                during the term of this Agreement, Quintiles agrees that it will                not enter                into any agreement to provide services which would in any way prevent                it                from providing the Services contemplated under this Agreement. Sponsor                agrees that it will not enter into an agreement with a third party                that                would alter or affect the regulatory obligations delegated to Quintiles                pursuant to this Agreement without the written consent of Quintiles,                which                will not be unreasonably withheld. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.0 | **Publication.**Project                results may not be published or referred to, in whole or in part,                by                Quintiles or its affiliates without the prior expressed written consent                of                Sponsor. Neither party will use the other party's name in connection                with                any publication or promotion without the other party's prior, written                consent. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 14.0 | **Limitation                of Liability.** |
|------|---------------------------------------------|

| 15.0 | Third                Party **Indemnification.**Sponsor                shall indemnify, defend and hold harmless Quintiles and its affiliates,                and its and their directors, officers, employees and agents (each,                a                “Quintiles Indemnified Party”), from and against any and all losses,                damages, liabilities, reasonable attorney fees, court costs, and                expenses                (collectively “Losses”), joint or several, resulting or arising from any                third-party claims, actions, proceedings, investigations or litigation                relating to or arising from or in connection with this Agreement                or the                Services contemplated herein (including, without limitation, any                Losses                arising from or in connection with any study, test, device, product                or                potential product to which this Agreement relates), except to the                extent                such Losses are determined to have resulted solely from the negligence                or                intentional misconduct of the Quintiles Indemnified Party seeking                indemnity hereunder. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 16.0 | **Indemnification                Procedure.**Quintiles                shall give Sponsor prompt notice of any third party                claim or lawsuit (including a copy thereof) served upon it and shall                fully                cooperate with Sponsor and its legal representatives in the investigation                of any matter the subject of indemnification. Quintiles shall not                unreasonably withhold its approval of the settlement of any claim,                liability, or action covered by this Indemnification                provision. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 17.0 | **Termination.**Sponsor                may terminate this Agreement without cause at any time during the                term of                the Agreement on sixty (60) day's prior written notice to Quintiles.                Either party may terminate this Agreement for material breach upon                thirty                (30) days' written notice specifying the nature of the breach, if                such                breach has not been substantially cured within the thirty (30) day                period.                During the 30-day cure period for termination due to breach, each                party                will continue to perform its obligations under the Agreement. If                the                termination notice is not due to a breach, or if the cure period                has                expired without a substantial cure of the breach, then the parties                shall                promptly meet to prepare a close-out schedule, and Quintiles shall                cease                performing all work not necessary for the orderly close-out of the                Services or required by laws or regulations. If Quintiles reasonably                determines that its continued performance of the Services contemplated                by                this Agreement, after discussion with Sponsor, would constitute a                violation of written regulatory or scientific standards of integrity,                then                Quintiles may terminate this Agreement by giving written notice stating                the effective date (which may be less than thirty days from the notice                date) of such termination. Either party may terminate this Agreement                immediately upon provision of written notice if the other party becomes                insolvent or files for bankruptcy. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 18.0 | **Relationship                with Affiliates.**Sponsor                agrees that Quintiles may use the services of its corporate affiliates                as                subcontractors to fulfill Quintiles' obligations under this Agreement.                Quintiles shall remain responsible for all obligations in connection                with                the Services performed by its affiliates, and its affiliates shall                be                subject to all of the terms, conditions and rights applicable to                Quintiles                under this Agreement. The term “affiliate” shall mean all entities                controlling, controlled by or under common control with Quintiles.                The                term “control” shall mean the ability to vote fifty percent (50%) or more                of the voting securities of any entity or otherwise having the ability                to                influence and direct the polices and direction of an                entity. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 19.0 | **Cooperation;                Sponsor Delays; Disclosure of Hazards.**Sponsor                shall forward to Quintiles in a timely manner all documents, materials                and                information in Sponsor's possession or control necessary for Quintiles                to                conduct the Services. Quintiles shall not be liable to Sponsor nor                be                deemed to have breached this Agreement for errors, delays or other                consequences arising from Sponsor's failure to timely provide documents,                materials or information or to otherwise cooperate with Quintiles                in order                for Quintiles to timely and properly perform its obligations, and                any such                failure by Sponsor shall automatically extend any timelines affected                by a                time period reasonably commensurate to take into account such failure,                unless Sponsor agrees in writing to pay any additional costs that                would be                required to meet the original timeline. If Sponsor delays a project                from                its agreed starting date or suspends performance of the project then                either: a) Sponsor will pay the standard daily rate of the Quintiles'                personnel assigned to the project, based on the percentage of their                time                allocated to the project, for the period of the delay, in order to keep                the current team members; or, b) Quintiles may re-allocate the personnel                at its discretion, and Sponsor will pay the costs of re-training                new                personnel. In addition, Sponsor will pay all non-cancelable costs                and                expenses incurred by Quintiles due to the delay and will adjust all                timelines to reflect additional time required due to the delay. Sponsor                shall provide Quintiles with all information available to it regarding                known or potential hazards associated with the use of any substances                supplied to Quintiles by Sponsor, and Sponsor shall comply with all                current legislation and regulations concerning the shipment of substances                by the land, sea or air. |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 20.0 | **Force                Majeure.**In                the event either party shall be delayed or hindered in or prevented                from                the performance of any act required hereunder by reasons of the forces                of                strike, lockouts, labor troubles, inability to procure materials                or                services, failure of power or restrictive government or judicial                orders,                or decrees, riots, insurrection, war, Acts of God, inclement weather                or                other reason or cause beyond that party's control, then performance                of                such act (except for the payment of money owed) shall be excused                for the                period of such delay on the basis that the relevant party will perform                all                reasonable actions to overcome any of the abovementioned                forces. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 21.0 | **Notices                and Deliveries.**Any                notice required or permitted to be given hereunder by either                party hereunder shall be in writing and shall be deemed given on                the date                received if delivered personally or by a reputable overnight delivery                service, or three (3) days after the date postmarked if sent by registered                or certified mail, return receipt requested, postage prepaid to the                following addresses: |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| If                to Quintiles:                                                                                                                                                                   | If                to Sponsor:                                                                                                                                     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                              |                                                                                                                                                              |
| Quintiles                Transnational Legal DepartmentP.O.                Box 13979Research                Triangle Park, North Carolina, U.S.A.27709-3979Attention:                John Russell | Prana                Biotechnology LtdLevel                2, 369 Royal Parade,Parkville,                VIC, 3052AustraliaAttention:                Dianne Angus |
|                                                                                                                                                                                              |                                                                                                                                                              |
| And,                                                                                                                                                                                              |                                                                                                                                                              |
|                                                                                                                                                                                              |                                                                                                                                                              |
| Quintiles                Transnational Legal Department Station                House Market                Street Bracknell                                                                       |                                                                                                                                                              |

----

| 22.0 | **Insurance.**During                the term of this Agreement to cover its obligations hereunder, the                parties                shall maintain insurance coverage with a reputable insurance company                as                follows: i)                Clinical Trials insurance for Sponsor of not less than AU$5,000,000                per                annum as provided                in Attachment 4 to this Agreement; ii) Professional Indemnity insurance                for Quintiles of not less than US$5,000,000 per annum; and, iii)                Liability                to third parties insurance                for Quintiles with a limit of $1,000,000 per claim or series of related                claims, or at                the minimum statutory level, whichever is greater, iv) Liability                to third                parties insurance                for Sponsor to AU$20,000,000 as provided in Attachment 4. For Quintiles,                all insurance                amounts may be obtained by full, individual primary policy amount;                a                primary amount of less than minimum requirement enhanced by a blanket                excess umbrella policy; or                a combination of either. Each party shall provide the other party                with a                certificate of insurance                upon request. Each party shall ensure that its policies shall contain                an                endorsement to the effect that it shall not be cancelled or otherwise                materially changed during                that period without thirty (30) days prior written notice to the                other                party. The certificates                specifying the above-referenced Sponsor insurances are provided in                Attachment 4 to this Agreement and is incorporated herein by                reference. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 23.0 | **Foreign                Currency Exchange.**The                currency to be used for invoice and payment shall be the                currency stated in the attached Budget or Table (the “Contracted                Currency”). If Quintiles                incurs pass-through costs in a currency other than the Contracted                Currency, then Sponsor                shall reimburse Quintiles for Quintiles' actual costs in the Contracted                Currency based                on the Oanda foreign currency exchange rate (Oanda.com)                for the applicable currencies on the last business day of the month                in                which such pass-through costs are submitted.                If a currency referenced within the Budget is replaced by the Euro                or                otherwise                ceases to become legal tender, the applicable replacement currency                will be                substituted for such currency for purposes of this provision at an                established conversion rate. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 24.0 | **Data                Protection.**Quintiles                and Sponsor agree to comply with all applicable privacy laws                and regulations. If the Project will involve the collection or processing                of personal data (as defined by applicable data protection legislation)                within the European Economic Area (“EEA”), then Sponsor shall serve as the                controller of such data, as defined by the European Union (“EU”) Data                Protection Directive (the “Directive”), and Quintiles shall act only under                the instructions of the Sponsor in regard to personal data. If Sponsor                is                not based in the EEA, Sponsor must appoint an EEA company to act                as its                local representative for data protection purposes in order to comply                with                the Directive, and such designation is attached hereto and incorporated                by                reference. If Sponsor does not have an affiliate in the EEA and requests                that a Quintiles affiliate in the EEA serve as its local representative,                then the parties shall negotiate a fee for such representative duties                and                shall enter into a Data Transfer Agreement between the parties containing                the Standard Contractual Clauses set forth by the EU Commission Decision                of 15 June 2001 (Decision 2001/497/EC) before Quintiles will assume                any                such representative duties. If Sponsor is not based in the EEA, Quintiles                will not export any personal data from the EEA unless Sponsor has                appointed a local representative. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 25.0 | **Binding                Agreement and Assignment.**This                Agreement shall be binding upon and inure to the benefit of Sponsor                and                Quintiles and their respective successors and permitted assigns.                Except as                stated above in Section 18, neither party may assign any of its rights                or                obligations under this Agreement to any party without the express,                written                consent of the other party. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 26.0 | **Choice                of Law, Waiver and Enforceability.**This                Agreement shall be construed, governed,                interpreted, and applied in accordance with the laws of England,                exclusive                of its conflicts of law provisions. The failure to enforce any right                or                provision herein shall not constitute a waiver of that right or provision.                Any waiver of a breach of a provision shall not constitute a waiver                of any                subsequent breach of that provision. If any provisions herein are                found to                be unenforceable on the grounds that they are overly broad or in                conflict                with applicable laws, it is the intent of the parties that such provisions                be replaced, reformed or narrowed so that their original business                purpose                can be accomplished                to the extent permitted by law, and that the remaining provisions                shall                not in                any way be affected or impaired                thereby. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 27.0 | **Survival.**The                rights and obligations of Sponsor and Quintiles, which by intent                or                meaning                have validity beyond such termination (including, but not limited                to,                rights with respect to inventions, confidentiality, discoveries and                improvements, indemnification and liability                limitations) shall survive the termination of this                Agreement. |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 28.0 | **Arbitration.**Any                controversy or claim arising out of or relating to this Agreement                or the                breach thereof shall be settled by arbitration administered by the                International Chamber of Commerce (“ICC”) under its International Rules of                Arbitration, and judgment on the award rendered by the arbitrator                shall be                binding and may be entered in any court having jurisdiction thereof.                Such                arbitration shall be filed and conducted at the office of the ICC                closest                to the Quintiles office having responsibility for the Project, and                shall                be conducted in                English by one arbitrator mutually acceptable to the parties selected                in                accordance with ICC                Rules. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 29.0 | **Entire                  Agreement, Headings and Modification.**This                  Agreement contains the entire understandings                  of the parties with respect to the subject matter herein, and supersedes                  all previous agreements (oral and written), negotiations and discussions.                  The descriptive headings                  of the sections of this Agreement are inserted for convenience                  only and                  shall not control                  or affect the meaning or construction of any provision hereof.                  Any                  modifications to the provisions herein must be in writing and signed                  by                  the parties. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **Quintiles                Limited** |                                       | **Prana                Biotechnology Limited** |
|--------------------------------------|--------------------------------------------|------------------------------------------------|
|                                 |                                       |                                           |
| By:                                  | \s\                Patricia Williams       |                                           | By: | /s/                [Illegible] |
|                                 | (signature)                                |                                           |   | (signature) |
| Print Name:                     | PATRICIA WILLIAMS                     |                                           | Print Name: | /s/                [Illegible] |
| Title:                               | VP, GLOBAL CONTRACTS             |                                           | Title: | [Illegible] |
| Date:                                | 1                3                NOV 2006 |                                           | Date: | 7th                November 2006 |

----

*LIST      OF A TTACHMENTS*

*ATTACHMENT      1—SCOPE OF WORK*

*ATTACHMENT      2—BUDGET AND PAYMENT SCHEDULE*

*ATTACHMENT      3—CLINICAL TRIAL AGREEMENT FORM*

*ATTACHMENT      4—INSURANCE CERTIFICATE*

----

**ATTACHMENT      1 **

**SCOPE      OF WORK**

| **Country** |   | **Sites** |   | **Patients****Screened** |   | **Patients****Randomised** |   | **Patients****Completing** |   |
|-------------|--------|-----------|--------|--------------------------|--------|----------------------------|--------|----------------------------|--------|
| SWEDEN      |   |      | 7      |                     |   | 100                        |   |                       | 80     |   |   | 33 |   |
|        |   |      | **7**  |                     |   | **100**                    |   |                       | **80** |   |   | **72** |   |

**GENERAL      STUDY ASSUMPTIONS **

| Phase                                                                                                       |   | II                                            |
|-------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------|
| Maximum                  number of active sites                                                             |   | 7                                             |
| Maximum                  number of patients screened                                                        |   | 100                                           |
| Number                  of patients randomised                                                              |   | 80                  (20% screen failure rate) |
| Number                  of patients evaluable                                                               |   | 72                  (10% drop-out rate)       |
| Recruitment                  period (months)                                                                |   | 4.00                                          |
| Treatment                  duration (months)                                                                |   | 3.00                                          |
| Follow                  up duration (months)                                                                |   | 0.00                                          |
| Maximum                  CRF pages per screen failure (including diary where                  applicable)   |   | 5                                             |
| Maximum                  CRF pages per drop-out (including diary where applicable)                          |   | 21                                            |
| Maximum                  CRF pages per complete patient (including diary where                  applicable) |   | 35                                            |
| Overall                  study length (months)                                                              |   | 14.96                                         |
| Number                  of client meetings                                                                  |   | 2                                             |
| Duration                  of client meetings (hours) -excluding travel                                      |   | 8                                             |
| Number                  of client teleconferences                                                           |   | 15                                            |
| Duration                  of client teleconferences (hours)                                                 |   | 1                                             |
| Number                  of investigator meetings                                                            |   | 1                                             |
| Duration                  of investigator meetings (hours) -excluding travel                                |   | 12                                            |

| **MONITORING                  ASSUMPTIONS**                                                          |   |                                    |
|------------------------------------------------------------------------------------------------------|--------|-----------------------------------------|
| Maximum                  number of sites identified                                                  |   | 13                                      |
| Maximum                  number of site selection visits                                             |   | 8                                       |
| Maximum                  number of site initiation visits                                            |   | 7                                       |
| Maximum                  number of monitoring visits                                                 |   | 49                  visits (7 per site) |
| -                  *Average                  time on site per monitoring visit (hours)*              |   | 5.00                                    |
| *-                  Average administrative time per monitoring visit                  (hours)*       |   | 5.00                                    |
| *-                  Average travel time per monitoring visit (hours)*                                |   | 5.00                                    |
| *-                  Average site contact between visits (hours per site per                  month)* |   | 2                  00                   |
| %                  SDV                                                                               |   | 100%                                    |
| Maximum                  number of close out visits                                                  |   | 7                                       |

----

| **MONITORING                ASSUMPTIONS**                                                        |   |                                  |
|--------------------------------------------------------------------------------------------------|--------|---------------------------------------|
| Maximum                number of sites identified                                                |   | 13                                    |
| Maximum                number of site selection visits                                           |   | 8                                     |
| Maximum                number of site initiation visits                                          |   | 7                                     |
| Maximum                number of monitoring visits                                               |   | 49                visits (7 per site) |
| -                *Average                time on site per monitoring visit (hours)*              |   | 5.00                                  |
| *-                Average administrative time per monitoring visit                (hours)*       |   | 5.00                                  |
| *-                Average travel time per monitoring visit (hours)*                              |   | 5.00                                  |
| *-                Average site contact between visits (hours per site per                month)* |   | 2                00                   |
| %                SDV                                                                             |   | 100%                                  |
| Maximum                number of close out visits                                                |   | 7                                     |

| **PHARMACOVIGILANCE                ASSUMPTIONS**                                                                                                                                          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Maximum                number of SAEs expected                                                                                                                                            |   | 24                SAEs (30%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Safety                database requirement                                                                                                                                                |   | Quintiles                Pharmacovigilance will set up a Clintrace Database                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| SAE                Coding                                                                                                                                                                 |   | Yes                - MedDRA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| SAE                Narratives                                                                                                                                                             |   | Yes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Quality                Control                                                                                                                                                            |   | 100%                QC of SAE data fields                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Tracking                database                                                                                                                                                          |   | A                tracking system will be set-up to track SAEs and                regulatory assessments to ensure open queries are efficiently identified                and prioritised, and                track submissions to regulatory authorities                                                                                                                                                                                                                                                                                                                                             |
| Number                of updates per SAE                                                                                                                                                  |   | Initial                and up to two (2) update reports per SAE assumed.                Cycle includes triage, case evaluation, follow-up                with sites (each SAE would generally require                2 follow-up communications with the respective                site to obtain answers to outstanding queries),                regulatory assessment, data entry, generation                of queries, quality control, medical review,                submission to Prana Biotechnology, and submission                to Regulatory Authorities. |
| Translation                of SAE documentation                                                                                                                                           |   | Quintiles                will provide translations of source documents                relating to SAEs using either an internal                medical translator or a medically certified translation                agency. These costs will be passed through                to the sponsor.                                                                                                                                                                                                                                                                                            |
| SAE                Reconciliation                                                                                                                                                         |   | Pharmacovigilance                will assist in the reconciliation                of the safety data in the safety and scientific databases (up to                7-10 data                fields per SAE)                                                                                                                                                                                                                                                                                                                                                                                           |
| Reporting                to Regulatory Authorities –                2 regulatory                reports (1 initial and 1 update) per expedited                SAE assumed |   | Quintiles                Pharmacovigilance will report up to 2 expedited                SAEs to Regulatory Authorities (including                the EMEA) as appropriate                                                                                                                                                                                                                                                                                                                                                                                                                            |

----

| **PHARMACOVIGILANCE                ASSUMPTIONS**                                                                                                                         |   |                                                                                                                                                                                                                                                                                            |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Investigator                alert letters (safety update letters) –2                alert letters (1 initial and 1 update) perexpedited                SAE assumed |   | Quintiles                Pharmacovigilance will prepare and distribute                non-personalised Investigator alert letters                for up to 2 expedited SAEs to 7 sites (28 mailings)                                                                                            |
| Expedited                SAE reports to be sent to Central Ethics Committees (CECs)                                                                                      |   | Quintiles                Pharmacovigilance will distribute up to 2 expedited SAEs (unblinded                if                required) to the applicable                CECs in the 1 EU/EEA country involved                in the study. Quintiles assumes 1 CEC per                country. |
| Cross-reporting                of expedited SAEs occurring in other protocols                                                                                            |   | Not                included in the budget                                                                                                                                                                                                                                                       |
| Interim/annual                regulatory reports                                                                                                                         |   | Not                included in the pharmacovigilance budget                                                                                                                                                                                                                                     |
| Meetings                to be attended by Pharmacovigilance personnel (number of                meetings)                                                                |   | 1                Client kick off meeting, 1 investigator meeting. Ongoing                communication between Quintiles' pharmacovigilance                group and Prana Biotechnology                has been included.                                                                      |
| Status                reports                                                                                                                                            |   | Monthly                                                                                                                                                                                                                                                                                         |

| **DATA                MANAGEMENT ASSUMPTIONS**                                                        |   |                                                                                                                                                              |
|-------------------------------------------------------------------------------------------------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CRF                design                                                                             |   | Quintiles                to design CRF                                                                                                                            |
| Database                platform                                                                      |   | Inform                EDC                                                                                                                                         |
| Duration                of data management (months)                                                   |   | 10.65                                                                                                                                                             |
| Number                of patient visits per complete CRF                                              |   | 6                                                                                                                                                                 |
| Maximum                number of CRF pages expected                                                   |   | 2,688                                                                                                                                                             |
| Number                of unique CRF pages                                                             |   | 11                                                                                                                                                                |
| Number                of repeating pages                                                              |   | 24                                                                                                                                                                |
| Number                of validation checks per page                                                   |   | 15                                                                                                                                                                |
| Total                validation checks programmed                                                     |   | 165                                                                                                                                                               |
| SAE                reconciliation required                                                            |   | Manual                                                                                                                                                            |
| Number                of electronic data sources                                                      |   | 1                                                                                                                                                                 |
| Total                number of electronic imports and transfers                                       |   | 10                (10 per source)                                                                                                                                 |
| Number                of database exports                                                             |   | 2                                                                                                                                                                 |
| Number                of queries per 100 pages                                                        |   | 3                                                                                                                                                                 |
| Total                queries to process                                                               |   | 81                                                                                                                                                                |
| Coding                dictionaries:                                                                   |   |                                                                                                                                                              |
| Diseases                                                                                              |   | MedDRA                                                                                                                                                            |
| Adverse                events                                                                         |   | MedDRA                                                                                                                                                            |
| Concomitant                medications                                                                |   | Internal                                                                                                                                                          |
| Number                of diseases per patient (up to 50% expected to autoencode)                      |   | 2                                                                                                                                                                 |
| Number                of adverse events per patient (up to 50% expected to                autoencode) |   | 3                                                                                                                                                                 |
| Number                of con meds per patient (up to 50% expected to autoencode)                      |   | 3                                                                                                                                                                 |
| Meetings                to be attended by DM personnel (number of meetings)                           |   | Client                kick off meeting (Y), investigator meeting (Y),                client teleconferences (15), client face to face meetings                (2) |

----

| **BIOSTATISTICS                ASSUMPTIONS**                                                                                                                                                                                                                                                                                |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Statistical                input to protocol development                                                                                                                                                                                                                                                                    |   | Yes                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Statistical                analysis plan responsibility                                                                                                                                                                                                                                                                     |   | Quintiles                will produce one draft of the analysis plan for review by Prana.                Prana                will provide one set of consolidated comments and the plan will be                considered                final upon incorporation of these comments.                Confirmation of the planned analyses will                be undertaken prior to database lock, and any minor                adjustments made at this time point. |
| Generate                randomisation schedule                                                                                                                                                                                                                                                                              |   | Yes                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Number                of treatment groups                                                                                                                                                                                                                                                                                   |   | 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Maximum                total number of tables                                                                                                                                                                                                                                                                               |   | 70                - Note: Table count refers to the number of entries in Table of                Contents                                                                                                                                                                                                                                                                                                                                                             |
| Maximum                total number of listings                                                                                                                                                                                                                                                                             |   | 30                - Note: Listings count refers to the number of entries in Table of                Contents                                                                                                                                                                                                                                                                                                                                                          |
| Maximum                total number of graphs                                                                                                                                                                                                                                                                               |   | 5                -                Note: Graph count refers to the number of entries in Table of                Contents                                                                                                                                                                                                                                                                                                                                               |
| Laboratory                data source                                                                                                                                                                                                                                                                                       |   | Single                Central                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Number                of interim analyses                                                                                                                                                                                                                                                                                   |   | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Type                of report required                                                                                                                                                                                                                                                                                      |   | Quintiles                will prepare an integrated report                                                                                                                                                                                                                                                                                                                                                                                                            |
| SAS                programming code to be delivered to customer                                                                                                                                                                                                                                                             |   | No                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Meetings                to be attended by Biostatistics personnel (number of                meetings)                                                                                                                                                                                                                       |   | Client                kick off meeting (1), no attendance at investigator                meeting, client teleconferences (4), no                attendance at client face to face meetings                                                                                                                                                                                                                                                                            |
|  Additional                Assumptions:                                                                                                                                                                                                                                                                                |
|  All              Statistical Outputs will undergo QC and Senior Biostatistical Review              before issue to Prana Biotechnology.                                                                                                                                                                               |
| Quintiles                will provide one draft set of Statistical Outputs for Review by Prana                Biotechnology, who will provideone                set of consolidated comments, and the Statistical Outputs will be                considered final upon incorporation of                thesecomments.  |
| Costs                will be adjusted in the event of differences between final client                requirements agreed in the Analysis Plan,Tables                and Listings and the assumptions listed                here.                                                                                      |

| **MEDICAL                ASSUMPTIONS**                   |   |                                                                                                                                                                  |
|----------------------------------------------------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Quintiles                to provide CRA training?        |   | Quintiles                is not responsible tor providing CRA training.                                                                                               |
| Medical                Monitoring (CRA and Site Support) |   | Quintiles                will provide medical monitoring throughout start up, recruitment,                treatment and close out phases of the                study. |

----

| **MEDICAL                WRITING ASSUMPTIONS**                                                                                                                                                                                                                                                                                                                                                                                           |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study                protocol                                                                                                                                                                                                                                                                                                                                                                                                            |   | Prana                to produce study protocol.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Clinical                Trial Report                                                                                                                                                                                                                                                                                                                                                                                                     |   | The                report will be based on an electronic template provided                by Prana, or prepared in Microsoft WORD                in a format compliant with ICH guidelines.                Inputs provided from Prana to the Medical                Writer will be in a format suitable for direct                incorporation into the report. The draft report                will undergo QC, medical and statistical reviews                within Quintiles before issue to Prana. Quintiles                will produce two drafts of the report for review                by Prana, who will provide one set of consolidated comments on each                draft.                The report will                be considered final upon incorporation of the second                draft comments. Costs will be adjusted in the event of appreciable                differences between the actual                final client requirements agreed in the Analysis                Plan and the final statistical outputs, we reserve                the right to renegotiate this quotation. |
| Report                Narratives                                                                                                                                                                                                                                                                                                                                                                                                         |   | An                estimated maximum 0 patient narratives will be                written in conjunction with the Clinical Trial Report,                Quintiles will provide one draft set of narratives                for review by Prana. Prana will provide one                set of consolidated comments and the narratives                will be considered final upon incorporation                of these comments.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Meetings                to be attended by Medical Writing personnel                (number of meetings)                                                                                                                                                                                                                                                                                                                                  |   | Client                teleconferences (2), client face to face meetings                (1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Additional                Assumptions                                                                                                                                                                                                                                                                                                                                                                                                    |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Any                Prana specific requirements for appendix documentation gathered by                Quintiles must be communicated upon contract agreement. Any documentation                to be provided by Prana for the report appendices will be provided                to the                Medical Writer before database lock, and in a format and quality                appropriate for direct inclusion in the report.    |
| Costs                do not include manipulation or editing of appendix documents, scanning                appendix documents, or through pagination of the report plus appendices.                The costs do not include copying of any completed CRFs for inclusion                in                the report appendices. One loose-leaf paper copy of the final report                is                included in the costings. |

----

**CENTRAL      LABORATORIES SCOPE OF WORK**

**Assignment      of responsibilities**

| **Task**                                  |   | **Quintiles** |   | **Prana** |
|-------------------------------------------|--------|---------------|--------|-----------|
| Screening                of Subjects      |   | **X**         |   |      |
| Analysis                of Safety Samples |   | **X**         |   |      |

**Study      Assumptions**

| Number                of included subjects |   | 80                Alzheimer Patients                                                          |
|--------------------------------------------|--------|-----------------------------------------------------------------------------------------------|
| Number                of Safety Samples    |   | 500                Samples                                                                    |
| Clinical                Chemistry:         |   | According                to Specification of Clinical Chemistry (See                Attached) |

| **Additional                Scope** |
|-------------------------------------|
| þ                              |   | Protocol                amendments |
| þ                              |   | Additional                protocol assessments not detailed in the protocol, i.e. laboratory                sampling etc. |
| þ                              |   | Regulatory                Affairs consulting (involving a technical review of proposed protocol                to                ensure that supportive data is in compliance with European                Regulations). |
| þ                              |   | Subjects                replaced due to study related withdrawals |
| þ                              |   | Courier                costs including documentation transportation |
| þ                              |   | Analysis                of additional safety samples SEK 1 734 |
| þ                              |   | Analyses                of samples at non-office hours SEK 1128 per hour |
| þ                              |   | Analysis                report in Excel format according to Quintiles standard, SEK analysis                price                x 2,75 |
| þ                              |   | Sample                preparations SEK 60 per sample |
| þ                              |   | Preparation                of labels SEK 1 128 per hour |
| þ                              |   | Analysis                of express samples SEK analysis price x 2,75 |
| þ                              |   | Sample                kits for PK samples 50 SEK per kit |
| þ                              |   | Non                Quintiles AB standard photocopying and faxing of source documents                to                Sponsor i.e. CRFs |
| þ                              |   | Storage                of samples and investigational product when clinical part of study                has                been completed |
| þ                              |   | Time                needed for any study specific audits performed by Sponsor or the                authorities. |

----

| **Description                  of services provided**                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| **1.**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | **Screening                  costs**                                                |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                |   |
| **Includes**haematology,                  biochemistry, hepatitis B, C, HIV, urinalysis, drug and alcohol                  screen.                                                                                                                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Screening                  labs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                |
| þ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 100                  samples                                                        | **SEK                  264,050** |
| þ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 100                  sampling kits à                  SEK                  50  |   |
| For study                  specific assessments please see “Specification of Clinical chemistry”.                                                                                                                                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| **2.**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | **In-study                  costs (including post-screen)**                         |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                |   |
| **In-**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | **study                  labs**                                                     |   |
| þ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 320                  samples                                                        | **SEK                  420,160** |
| þ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 320                  sampling kits à SEK 50                               |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                |   |
| Post                  study labs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                |
| þ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 80                  samples                                                         | **SEK                  114,640** |
| þ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 80                  sampling kits à SEK 50                                |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                |   |
| CSF                  Sample Kits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                |
| þ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                | **SEK                  9 000** |
| þ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 180                  sampling kits at SEK 50                                        |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                |   |
| **A.**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                |   |
| **B.**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                |   |
| **C.**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | ***Also                  included in clinical chemistry services***                 |   |
| þ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Sample                  description                                                 |   |
| þ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Written                  analytical report in Quintiles AB format, by fax and mail. |   |
| þ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Retention                  of study data for 10 years.                              |   |
| See                  also “Specification of Clinical chemistry”                                                                             Time limit                                        |                                                                                |
| Projects                  will be active for 12 months following completion of the last scheduled                  activity (e.g. last subject out or final report). Any requests                  for data                  clarifications, copies of archived documentation or similar will                  be                  handled within the specified budget during this 12-month period.                  Thereafter any services will be charged at Quintiles current hourly                  rates. |

----

**Specification      of clinical chemistry**

| **Haematology**                                 |   | **Screening** |   | **During** |   | **Follow****Up** |   |
|-------------------------------------------------|--------|---------------|--------|------------|--------|------------------|--------|
| B-Differential                white blood cells |   |          | 1      |       |   | 4                |   |   | 1 |   |
| B-Eryt.                Sediment.rate            |   |          |   |       |   |             |   |   |   |   |
| B-Heamoglobin                                   |   |          | 1      |       |   | 4                |   |   | 1 |   |
| B-Hematocrit                (EVF)               |   |          | 1      |       |   | 4                |   |   | 1 |   |
| B-MCH                                           |   |          |   |       |   |             |   |   |   |   |
| B-MCHC                                          |   |          | 1      |       |   | 4                |   |   | 1 |   |
| B-MCV                                           |   |          | 1      |       |   | 4                |   |   | 1 |   |
| B-Platelets                                     |   |          | 1      |       |   | 4                |   |   | 1 |   |
| B-Red                Blood cells                |   |          | 1      |       |   | 4                |   |   | 1 |   |
| B-Reticulocytes                                 |   |          |   |       |   |             |   |   |   |   |
| B-White                blood cells              |   |          | 1      |       |   | 4                |   |   | 1 |   |
| Extra                haematology analysis       |   |          |   |       |   |             |   |   |   |   |
| **Coagulation**                                 |   |          |   |       |   |             |   |   |   |   |
| P-APTT                                          |   |          |   |       |   |             |   |   |   |   |
| P-Prothrombin                complex            |   |          |   |       |   |             |   |   |   |   |
| Fibrinogen                                      |   |          |   |       |   |             |   |   |   |   |
| Antithrombin                III                 |   |          |   |       |   |             |   |   |   |   |
| Fibrin                D-Dimer                   |   |          |   |       |   |             |   |   |   |   |
| **Clinical                Chemistry**           |   |          |   |       |   |             |   |   |   |   |
| HbAlC                                           |   |          |   |       |   |             |   |   |   |   |
| A/G                ratio                        |   |          |   |       |   |             |   |   |   |   |
| Laktat                                          |   |          |   |       |   |             |   |   |   |   |
| S-ALAT                                          |   |          | 1      |       |   | 4                |   |   | 1 |   |
| S-Albumin                                       |   |          | 1      |       |   | 4                |   |   | 1 |   |
| S-alfal-Microglobuline                          |   |          |   |       |   |             |   |   |   |   |
| S-Alkaline                phosphat              |   |          | 1      |       |   | 4                |   |   | 1 |   |
| S-Amylase                                       |   |          |   |       |   |             |   |   |   |   |
| S-ASAT                                          |   |          | 1      |       |   | 4                |   |   | 1 |   |
| S-beta2-Microglobuline                          |   |          |   |       |   |             |   |   |   |   |
| S-Bicarbonate                                   |   |          |   |       |   |             |   |   |   |   |
| S-Bilirubin                (conjug)             |   |          |   |       |   |             |   |   |   |   |
| S-Bilirubin                (total)              |   |          | 1      |       |   | 4                |   |   | 1 |   |
| S-Bilirubin                (unconj.)            |   |          |   |       |   |             |   |   |   |   |
| S-Calcium                                       |   |          | 1      |       |   | 4                |   |   | 1 |   |

----

| S-Calcium                (albmodif)       |   |   |   |   |   |   |   |   |   |   |
|-------------------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| S-Chloride                                |   |   |   |   |   |   |   |   |   |   |
| S-Cholesterol                             |   |   |   |   |   |   |   |   |   |   |
| S-Creatinine                kinase        |   |   |   |   |   |   |   |   |   |   |
| S-Creatine                kinase MB       |   |   |   |   |   |   |   |   |   |   |
| S-Creatinine                              |   |   | 1      |   |   | 4      |   |   | 1      |   |
| S-CRP                                     |   |   |   |   |   |   |   |   |   |   |
| S-Cystatin                C               |   |   |   |   |   |   |   |   |   |   |
| S-Ferritin                                |   |   | 1      |   |   | 4      |   |   | 1      |   |
| S-Free                fatty acid          |   |   |   |   |   |   |   |   |   |   |
| S-Fruktosamine                            |   |   |   |   |   |   |   |   |   |   |
| S-GGT                                     |   |   | 1      |   |   | 4      |   |   | 1      |   |
| S-Glucose                                 |   |   | 1      |   |   |   |   |   |   |   |
| S-Haptoglobin                             |   |   |   |   |   |   |   |   |   |   |
| S-HDL                                     |   |   |   |   |   |   |   |   |   |   |
| S-Iron                                    |   |   | 1      |   |   | 4      |   |   | 1      |   |
| S-LD                                      |   |   |   |   |   |   |   |   |   |   |
| S-LDL                                     |   |   |   |   |   |   |   |   |   |   |
| S-Magnesium                               |   |   |   |   |   |   |   |   |   |   |
| S-N-acetylglucosaminidase                 |   |   |   |   |   |   |   |   |   |   |
| S-Orosomucoid                             |   |   |   |   |   |   |   |   |   |   |
| S-Osmolality                              |   |   |   |   |   |   |   |   |   |   |
| S-Phosphate                               |   |   | 1      |   |   | 4      |   |   | 1      |   |
| S-Potassium                               |   |   | 1      |   |   | 4      |   |   | 1      |   |
| S-Protein                (total)          |   |   | 1      |   |   | 4      |   |   | 1      |   |
| S-Sodium                                  |   |   | 1      |   |   | 4      |   |   | 1      |   |
| S-TIBC                                    |   |   |   |   |   |   |   |   |   |   |
| S-Transferrin                             |   |   |   |   |   |   |   |   |   |   |
| S-Triglycerides                           |   |   |   |   |   |   |   |   |   |   |
| S-UREA                                    |   |   | 1      |   |   | 4      |   |   | 1      |   |
| S-Uric                Acid                |   |   |   |   |   |   |   |   |   |   |
| S-TIBC                                    |   |   |   |   |   |   |   |   |   |   |
| S-Myoglobin                               |   |   |   |   |   |   |   |   |   |   |
| S-                Zinc (External Lab)     |   |   | 1      |   |   | 4      |   |   | 1      |   |
| S-                Copper ( External Lab ) |   |   | 1      |   |   | 4      |   |   | 4      |   |
| Extra                serum analyses       |   |   |   |   |   |   |   |   |   |   |
| ***Urine***                               |   |   |   |   |   |   |   |   |   |   |
| Creatinine                clearance       |   |   | 1      |   |   | 4      |   |   | 1      |   |

----

| Creatinine                clearance according to customer |   |   |    |   |   |   |   |   |   |   |
|-----------------------------------------------------------|--------|--------|---------|--------|--------|--------|--------|--------|--------|--------|
| U-Albumin                                                 |   |   |    |   |   |   |   |   |   |   |
| U-Alkaline                Phosphatase                     |   |   |    |   |   |   |   |   |   |   |
| U-alpha                1 -Microglobuline                  |   |   |    |   |   |   |   |   |   |   |
| U-beta2-Microglobuline                                    |   |   |    |   |   |   |   |   |   |   |
| U-Chloride                                                |   |   |    |   |   |   |   |   |   |   |
| U-Creatinine                                              |   |   |    |   |   |   |   |   |   |   |
| U-GGT                                                     |   |   |    |   |   |   |   |   |   |   |
| U-Glucose                                                 |   |   |    |   |   |   |   |   |   |   |
| U-LD                                                      |   |   |    |   |   |   |   |   |   |   |
| U-N-acetylglucosaminidase                                 |   |   |    |   |   |   |   |   |   |   |
| U-Osmolality                                              |   |   |    |   |   |   |   |   |   |   |
| U-Potassium                                               |   |   |    |   |   |   |   |   |   |   |
| U-Pregnancy                test                           |   |   |    |   |   |   |   |   |   |   |
| U-Sediment                                                |   |   |    |   |   |   |   |   |   |   |
| U-Sodium                                                  |   |   |    |   |   |   |   |   |   |   |
| U-Urea                                                    |   |   |    |   |   |   |   |   |   |   |
| Urine                Microscopy for Casts and RBC         |   |   | 1       |   |   |   |   |   | 1      |   |
| Extra                urine analysis                       |   |   |    |   |   |   |   |   |   |   |
| Extra                urine analysis                       |   |   |    |   |   |   |   |   |   |   |
| ***U-stix***                                              |   |   |    |   |   |   |   |   |   |   |
| U-Bilirubin                                               |   |   | 1       |   |   | 4      |   |   | 1      |   |
| U-Glucose                                                 |   |   | 1       |   |   | 4      |   |   | 1      |   |
| U-Ketones                                                 |   |   | 1       |   |   | 4      |   |   | 1      |   |
| U-Nitrite                                                 |   |   | 1       |   |   | 4      |   |   | 1      |   |
| U-Opiates                                                 |   |   | 1       |   |   | 4      |   |   | 1      |   |
| U-pH                                                      |   |   | 1       |   |   | 4      |   |   | 1      |   |
| U-Protein                                                 |   |   | 1       |   |   | 4      |   |   | 1      |   |
| U-Red                blood cells                          |   |   | 1       |   |   | 4      |   |   | 1      |   |
| U-Specific                Gravity                         |   |   | 1       |   |   | 4      |   |   | 1      |   |
| U-Urobilinogen                                            |   |   |  1 |   |   | 4      |   |   | 1      |   |
| U-White                blood cells                        |   |   | 1       |   |   | 4      |   |   | 1      |   |
| **Other                analyses**                         |   |   |    |   |   |   |   |   |   |   |
| S-Anti-HCV                                                |   |   | 1       |   |   |   |   |   |   |   |
| S-Anti-HIVl/HIV2                                          |   |   | 1       |   |   |   |   |   |   |   |
| S-B12                                                     |   |   | 1       |   |   | 4      |   |   | 1      |   |

----

| Cobalamine                                            |   |   |                        |   |   |                       |   |
|-------------------------------------------------------|--------|--------|-----------------------------|--------|--------|----------------------------|--------|
| S-E2                                                  |   |   |                        |   |   |                       |   |
| S-Estradiol                                           |   |   |                        |   |   |                       |   |
| FOB                                                   |   |   |                        |   |   |                       |   |   |   |   |
| S-Folat                                               |   |   | 1                           |   |   | 4                          |   |   | 1 |   |
| S-FSH                ( half the population)           |   |   | 1                           |   |   |                       |   |   |   |   |
| S-fT4                                                 |   |   |                        |   |   |                       |   |   |   |   |
| S-fT3                                                 |   |   |                        |   |   |                       |   |   |   |   |
| Hbc                IgM                                |   |   |                        |   |   |                       |   |   |   |   |
| S-HBsAg                                               |   |   | 1                           |   |   |                       |   |   |   |   |
| S-hCG                                                 |   |   |                        |   |   |                       |   |   |   |   |
| S-Helicobakter                Pylori                  |   |   |                        |   |   |                       |   |   |   |   |
| S-Hepatitis                A IgM                      |   |   | 1                           |   |   |                       |   |   |   |   |
| S-Insulin                                             |   |   |                        |   |   |                       |   |   |   |   |
| S-Luteinizing                Hormone (LH)             |   |   |                        |   |   |                       |   |   |   |   |
| S-Prolactine                                          |   |   |                        |   |   |                       |   |   |   |   |
| RBC-Folat                                             |   |   |                        |   |   |                       |   |   |   |   |
| S-Pregnancy                test                       |   |   |                        |   |   |                       |   |   |   |   |
| S-Sex                Hormone Binding Globuline (SHBG) |   |   |                        |   |   |                       |   |   |   |   |
| S-Testosterone                                        |   |   |                        |   |   |                       |   |   |   |   |
| S-TSH                                                 |   |   | 1                           |   |   |                       |   |   |   |   |
| CSF                Analyses ( External Lab)           |   |   |                        |   |   |                       |   |   |   |   |
| Zinc                                                  |   |   | 1                (Baseline) |   |   | 1                (Visit 6) |   |   |   |   |
| Copper                                                |   |   | 1                (Baseline) |   |   | 1                (Visit 6) |   |   |   |   |

----

**TIMELINES**

| **Timelines**                                          |
|--------------------------------------------------------|
| Quintiles                involvement begins            | May                2006 |
| First                patient in                        | September                2006 |
| Last                patient in                         | December                2006 |
| Last                patient out                        | April                2007 |
| Database                lock                           | May                2007 |
| Availability                of all statistical outputs | June                2007 |
| Draft                integrated clinical trial report  | Mid                June 2007 |
| Final                integrated clinical trial report  | Mid                July 2007 |
| Quintiles                involvement ends              | August                2007 |

----

**ATTACHMENT      2 **

**BUDGET      AND PAYMENT SCHEDULE**

| **ACTIVITY**                                                              |   | **UNIT** |                              | **NUMBER****OF UNITS** |   | **COST/UNIT** |   | **TOTAL****HOURS** |      | **TOTAL****COST ($)** |           | **ASSUMPTIONS** |   |
|---------------------------------------------------------------------------|--------|----------|-----------------------------------|-----------------------------|--------|---------------|--------|--------------------|-----------|----------------------------|----------------|-----------------|--------|
| **STUDY                MATERIAL DEVELOPMENT**                             |   |     |                              |                        |   |          |   |               |      |                       |           | **68.00**       |   |   | **12,663.00** |   |   |   |   |
| Protocol                development/review                                |   |     | Protocol                          |                        |   | 1.00          |   |               | 1,673.00  |                       |           | 8.00            |   |   | 1,673.00 |   |   |   |   |
| CRF                development/review                                     |   |     | CRF                               |                        |   | 1.00          |   |               | 1,389.00  |                       |           | 8.00            |   |   | 1,389.00 |   |   |   |   |
| Study                reference manual                                     |   |     | Manual                            |                        |   | 1.00          |   |               | 9,601.00  |                       |           | 52.00           |   |   | 9,601.00 |   |   |   |   |
|                                                                      |   |     |                              |                        |   |          |   |               |      |                       |           |            |   |   |   |   |   |   |   |
| **STUDY                START-UP**                                         |   |     |                              |                        |   |          |   |               |      |                       |           | **542.00**      |   |   | **107,235.00** |   |   |   |   |
| Kick-off                meeting                                           |   |     | Meeting                           |                        |   | 1.00          |   |               | 20,994.00 |                       |           | 120.00          |   |   | 20,994.00 |   |   | 1 Kick off meeting,attended by PM, PA,CTL, CTA, DM Lead,Biostats and                Pharmacovigilance |   |
|                                                                      |   |     |                              |                        |   |          |   |               |      |                       |           |            |   |   |   |   |   |   |   |
| Project                planning and team training                         |   |     | Study                             |                        |   | 1.00          |   |               | 18,827.00 |                       |           | 70.00           |   |   | 18,827.00 |   |   |   |   |
| Site                identification                                        |   |     | Identified                site    |                        |   | 13.00         |   |               | 623.92    |                       |           | 41.00           |   |   | 8,111.00 |   |   |   |   |
| Site                selection visits                                      |   |     | Visit                             |                        |   | 8.00          |   |               | 2,600.75  |                       |           | 104.00          |   |   | 20,806.00 |   |   |   |   |
| Ethics                committee applications                              |   |     | Application                       |                        |   | 1.00          |   |               | 857.29    |                       |           | 30.00           |   |   | 6,001.00 |   |   |   |   |
| Negotiate                investigator contracts                           |   |     | Initiated                site     |                        |   | 7.00          |   |               | 1,067.86  |                       |           | 42.00           |   |   | 7,475.00 |   |   |   |   |
| Site                initiation visits                                     |   |     | Visit                             |                        |   | 7.00          |   |               | 3,000.71  |                       |           | 105.00          |   |   | 21,005.00 |   |   |   |   |
| Assemble                and ship study documents                          |   |     | Initiated                site     |                        |   | 7.00          |   |               | 573.71    |                       |           | 30.00           |   |   | 4,016.00 |   |   |   |   |
|                                                                      |   |     |                              |                        |   |               |   |               |      |                       |           |            |   |   |   |   |   |   |   |
| **REGULATORY                ACTIVITIES**                                  |   |     |                              |                        |   |          |   |               |      |                       |           | **77.00**       |   |   | **12,379.00** |   |   |   |   |
| Regulatory                Support & Consulting                        |   |     | Study                month        |                        |   | 14.96         |   |               | 216.02    |                       |           | 16.00           |   |   | 3,232.00 |   |   |   |   |
| Submission                of Regulatory Applications                      |   |     | Country                submission |                        |   | 1.00          |   |               | 8,158.00  |                       |           | 55.00           |   |   | 8,158.00 |   |   |   |   |
| European                Clinical Trial Directive Compliance               |   |     | Study                             |                        |   | 1.00          |   |               | 989.00    |                       |           | 6.00            |   |   | 989.00 |   |   |   |   |
|                                                                      |   |     |                              |                        |   |          |   |               |      |                       |           |            |   |   |   |   |   |   |   |
| **INVESTIGATOR                MEETING**                                   |   |     |                              |                        |   |          |   |               |      |                       |           | **144.00**      |   |   | **28,739.00** |   |   |   |   |
| Meeting                planning and coordination                          |   |     | Meeting                           |                        |   | 1.00          |   |               | 10,414.00 |                       |           | 44.00           |   |   | 10,414.00 |   |   | 1                Investigator Meeting,attended                by PM, CTL,CTA,                DM Lead, Pharmacovigilance |   |
|                                                                      |   |     |                              |                        |   |          |   |               |      |                       |           |            |   |   |   |   |   |   |   |
| Meeting                travel and attendance                              |   |     | Meeting                           |                        |   | 1.00          |   |               | 18,325.00 |                       |           | 100.00          |   |   | 18,325.00 |   |   |   |   |
|                                                                      |   |     |                              |                        |   |          |   |               |      |                       |           |            |   |   |   |   |   |   |   |
| **CLINICAL                MONITORING & SITE** **MANA****GEMENT** |   |     |                              |                        |   |          |   | **1,062.00**       |      |                       | **206,719.00** |            |   |   |   |
| Interim                monitoring visits                                  |   |     | Visit                             |                        |   | 49.00         |   |               | 3,132.80  |                       |           | 756.00          |   |   | 153,507.00 |   |   |   |   |
| Site                contact/in-house monitoring                           |   |     | Clinical                month     |                        |   | 12.19         |   |               | 3,095.31  |                       |           | 196.00          |   |   | 37,739.00 |   |   |   |   |
| Maintenance                of study files                                 |   |     | Clinical                month     |                        |   | 12.19         |   |               | 1,009.57  |                       |           | 91.00           |   |   | 12,309.00 |   |   |   |   |
| Investigator                Payment Administration                        |   |     | Payment                           |                        |   | 4.06          |   |               | 778.52    |                       |           | 19.00           |   |   | 3,164.00 |   |   | Assumes                quarterly                payments |   |
|                                                                      |   |     |                              |                        |   |          |   |               |      |                       |           |            |   |   |   |   |   |   |   |
| **SITE                CLOSE-OUT**                                         |   |     |                              |                        |   |          |   |               |      |                       |           | **131.00**      |   |   | **27,044.00** |   |   |   |   |
| Close-out                visits                                           |   |     | Visit                             |                        |   | 7.00          |   |               | 3,708.86  |                       |           | 126.00          |   |   | 25,962.00 |   |   |   |   |
| Study                archiving                                            |   |     | Active                site        |                        |   | 7.00          |   |               | 154.57    |                       |           | 5.00            |   |   | 1,082.00 |   |   |   |   |
|                                                                      |   |     |                              |                        |   |          |   |               |      |                       |           |            |   |   |   |   |   |   |   |
| **MEDICAL                SUPPORT**                                        |   |     |                              |                        |   |          |   |               |      |                       |           | **188.00**      |   |   | **45,174.00** |   |   |   |   |
| CRA                and site support                                       |   |     | Study                month        |                        |   | 14.96         |   |               | 3,019.34  |                       |           | 188.00          |   |   | 45,174.00 |   |   |   |   |

----

| **PHARMACOVIGILANCE**                                        |   |   |                          |   |   |       |   |   |      |   |   | **383.00**   |   |   | **61,142.00**  |   |   |   |   |
|--------------------------------------------------------------|--------|--------|-------------------------------|--------|--------|------------|--------|--------|-----------|--------|--------|--------------|--------|--------|----------------|--------|--------|--------|--------|
| Safety                database and project set-up            |   |   | Study                         |   |   | 1.00       |   |   | 18,048.00 |   |   | 94.00        |   |   | 18,048.00      |   |   |   |   |
| SAE                processing                                |   |   | SAE                           |   |   | 24.00      |   |   | 1,188.58  |   |   | 216.00       |   |   | 28,526.00      |   |   |   |   |
| Medical                review of SAEs                        |   |   | SAE                           |   |   | 24.00      |   |   | 271.71    |   |   | 24.00        |   |   | 6,521.00       |   |   |   |   |
| Regulatory                reporting                          |   |   | Expedited                SAE  |   |   | 2.00       |   |   | 678.50    |   |   | 9.00         |   |   | 1,357.00       |   |   |   |   |
| Investigator                alert letters                    |   |   | Alert                letter   |   |   | 28.00      |   |   | 17.68     |   |   | 4.00         |   |   | 495.00         |   |   |   |   |
| Project                administration and system maintenance |   |   | Clinical                month |   |   | 12.19      |   |   | 508.11    |   |   | 36.00        |   |   | 6,195.00       |   |   |   |   |
|                                                         |   |   |                          |   |   |       |   |   |      |   |   |         |   |   |           |   |   |   |   |
| **DATA                MANAGEMENT**                           |   |   |                          |   |   |       |   |   |      |   |   | **961.00**   |   |   | **110,588.00** |   |   |   |   |
| Database                design and build                     |   |   | Unique                CRF     |   |   | 11.00      |   |   | 4,877.73  |   |   | 480.00       |   |   | 53,655.00      |   |   |   |   |
| Database                QC                                   |   |   | Patient                       |   |   | 80.00      |   |   | 8.69      |   |   | 4.00         |   |   | 695.00         |   |   |   |   |
| Data                monitoring                               |   |   | DCF                issued     |   |   | 81.00      |   |   | 98.05     |   |   | 97.00        |   |   | 7,942.00       |   |   |   |   |
| Data                import/export                            |   |   | Import                        |   |   | 10.00      |   |   | 371.10    |   |   | 34.00        |   |   | 3,711.00       |   |   |   |   |
| Database                maintenance and management           |   |   | DM                month       |   |   | 10.65      |   |   | 2,697.84  |   |   | 235.00       |   |   | 28,732.00      |   |   |   |   |
| Data                coding                                   |   |   | Coded                item     |   |   | 640.00     |   |   | 7.88      |   |   | 57.00        |   |   | 5,040.00       |   |   |   |   |
| EDC                training                                  |   |   | Study                         |   |   | 1.00       |   |   | 10,813.00 |   |   | 54.00        |   |   | 10,813.00      |   |   |   |   |
|                                                         |   |   |                          |   |   |       |   |   |      |   |   |         |   |   |           |   |   |   |   |
| **BIOSTATISTICS**                                            |   |   |                          |   |   |       |   |   |      |   |   | **788.00**   |   |   | **118,966.00** |   |   |   |   |
| Consulting                and analysis plan                  |   |   | Study                         |   |   | 1.00       |   |   | 25,295.00 |   |   | 162.00       |   |   | 25,295.00      |   |   |   |   |
| Data                manipulation                             |   |   | Study                         |   |   | 1.00       |   |   | 26,663.00 |   |   | 197.00       |   |   | 26,663.00      |   |   |   |   |
| Final                tables, figures and listings            |   |   | Output                        |   |   | 105.00     |   |   | 509.54    |   |   | 391.00       |   |   | 53,502.00      |   |   |   |   |
| DSMB                support                                  |   |   | Study                         |   |   |  1.00 |   |   | 7,958.00  |   |   |  37.50  |        |   |  7,958.00 |   |   |   |   |
| Biostatistical                report                         |   |   | Report                        |   |   | 1.00       |   |   | 5,548.00  |   |   | 38.00        |   |   | 5,548.00       |   |   |   |   |
|                                                         |   |   |                          |   |   |       |   |   |      |   |   |         |   |   |           |   |   |   |   |
| **MEDICAL                WRITING**                           |   |   |                          |   |   |       |   |   |      |   |   | **265.00**   |   |   | **51,977.00**  |   |   |   |   |
| Integrated                study report                       |   |   | Report                        |   |   | 1.00       |   |   | 51,977.00 |   |   | 265.00       |   |   | 51,977.00      |   |   |   |   |
|                                                         |   |   |                          |   |   |       |   |   |      |   |   |         |   |   |           |   |   |   |   |
| **PROJECT                MANAGEMENT**                        |   |   |                          |   |   |       |   |   |      |   |   | **1,869.00** |   |   | **403,802.00** |   |   |   |   |
| Project                management                            |   |   | Study                month    |   |   | 14.96      |   |   | 5,762.31  |   |   | 413.00       |   |   | 86,213.00      |   |   |   |   |
| Clinical                management                           |   |   | Clinical                month |   |   | 12.19      |   |   | 16,795.51 |   |   | 919.00       |   |   | 214,951.00     |   |   |   |   |
| Client                meetings                               |   |   | Meeting                       |   |   | 2.00       |   |   | 18,793.50 |   |   | 188.00       |   |   | 37,587.00      |   |   |   |   |
| Client                teleconferences                        |   |   | Teleconference                |   |   | 14.96      |   |   | 766.30    |   |   | 59.00        |   |   | 11,465.00      |   |   |   |   |
| Internal                team meetings                        |   |   | Study                month    |   |   | 14.96      |   |   | 3,581.58  |   |   | 290.00       |   |   | 53,586.00      |   |   |   |   |
|                                                         |   |   |                          |   |   |       |   |   |      |   |   |         |   |   |           |   |   |   |   |

----

| **Services**                                                    |   | **Cost                (SEK)** |                              | **Cost                (USD)** |   |
|-----------------------------------------------------------------|--------|-------------------------------|-----------------------------------|-------------------------------|--------|
| **Screening                Costs**                              |   |                          |                              |                          |   |   |   |
| Screening                labs                                   |   |                          | 264,050                           |                          |   | 36,944 |   |
| In-study                labs (incl post-study)                  |   |                          | 534,800                           |                          |   | 74,826 |   |
| **Administrating/Shipping                Costs**                |   |                          |                              |                          |   |   |   |
| Administration                Clinical Chemistry                |   |                          | 28,782                            |                          |   | 3,643 |   |
| Sample                kit Blood 50SEK/Kit                       |   |                          | 25,000                            |                          |   | 3,498 |   |
| Sample                Kits CSF 50SEK/Kit                        |   |                          | 9,000                             |                          |   | 1,259 |   |
| **Total****Discount                of 5% on Professional Fees** |   |                          | **861,632****-43,081****818,551** |                          |   | **120,554****-6,027****114,527** |   |

**Additional      Sa**
**mples      to be analysed at Karolinska Hospital Laboratory**

| **Services**                                  |   | **Cost                (SEK)** |        | **Cost                (USD)** |   |
|-----------------------------------------------|--------|-------------------------------|-------------|-------------------------------|--------|
| **Sample**                                    |   |                          |        |                          |   |   |   |
| S-Zinc                480x194SEK              |   |                          | 93,120      |                          |   | 13,035 |   |
| S-Copper                480x210SEK            |   |                          | 100,800     |                          |   | 14,110 |   |
| CSF-Zinc160x194SEK                            |   |                          | 31,040      |                          |   | 4,346 |   |
| CSF-Copper160x512SEK                          |   |                          | 81,920      |                          |   | 11,470 |   |
| **Total                (External LAB Costs)** |   |                          | **306,880** |                          |   | **42,961** |   |

**TOTAL**

| Quintiles                Laboratory             |   |   | 818,551                          |   |   | 114,527                        |   |
|-------------------------------------------------|--------|--------|----------------------------------|--------|--------|--------------------------------|--------|
| Karolinska                Laboratory (External) |   |   | 306,880                          |   |   | 42,961                         |   |
| **Total                Cost**                   |   |   | **1,125,431                SEK** |   |   | **157,488                USD** |   |

| **TOTAL                LABOUR FEES**            |   |   | **1,343,916.00** |   |
|-------------------------------------------------|--------|--------|------------------|--------|
|                                            |   |   |             |   |
| **Study                Passthroughs**           |   |   | **117,980.16**   |   |
| Regulatory                expenses              |   |   | 6,460.00         |   |
| Investigator                meeting expenses    |   |   | 11,100.00        |   |
| Clinical                monitoring travel       |   |   | 34,944.00        |   |
| Client/training                meeting expenses |   |   | 37,762.00        |   |
| Translations                                    |   |   | 886.00           |   |
| Printing                & courier costs     |   |   | 2,217.48         |   |
| Other                expenses (specify)         |   |   | 22,624.68        |   |
|                                            |   |   |             |   |
| **GRAND                TOTAL**                  |   |   | **1,461,896.16** |   |

| **Currency Exchange Rate Effective as of:** | ** ** | **Wed:                l-Feb-2006** |
|----------------------------------------------------------------------|------------|------------------------------------|
| **Proposal                Currency:**                                | ** ** | **US                Dollar**       |
| **Exchange                Rates:**                                   | ** ** | **1USD                =**          |
| ** **                                                           | ** ** | **0.8257**                         | **   EUR  ** | **Euro** |
| ** **                                                           | ** ** | **1**                              | **USD** | **US                Dollar** |
| ** **                                                           | ** ** | **0.5643**                         | **GBP** | **United Kingdom Pound** |
| ** **                                                           | ** ** | **7.6182**                         | **SEK** | **Swedish                Krona** |

----

**PAYMENT      SCHEDULE**

**Professional      Fees **

**Milestone      Payments**

| **Milestone**                                  |   | ** Total                (USD)** |        |
|------------------------------------------------|--------|--------------------------------------|-------------|
| Signature                of LOI                |   |                                 | 116,083     |   |
| Signature                of GSA                |   |                                 | 107,513     |   |
| 25%                of Patients Randomised      |   |                                 | 89,789      |   |
| 75%                of Patients Randomised      |   |                                 | 89,789      |   |
| Last                Patient In Treatment Start |   |                                 | 53,757      |   |
| 100%                Sites Closed               |   |                                 | 53,752      |   |
| Quintiles                Involvement Ends      |   |                                 | 26,878      |   |
| **Total**                                      |   |                                 | **537,561** |   |

**Monthly        Payments**

| **Month**                      |   | ** Total                (USD)** |          |
|--------------------------------|--------|--------------------------------------|---------------|
| July                2006       |   |                                 | 62,027        |   |
| August,                2006    |   |                                 | 62,027        |   |
| September,                2006 |   |                                 | 62,027        |   |
| October,                2006   |   |                                 | 62,027        |   |
| November,                2006  |   |                                 | 62,027        |   |
| December,                2006  |   |                                 | 62,027        |   |
| January,                2007   |   |                                 | 62,027        |   |
| February,                2007  |   |                                 | 62,027        |   |
| March,                2007     |   |                                 | 62,027        |   |
| April,                2007     |   |                                 | 62,027        |   |
| May,                2007       |   |                                 | 62,027        |   |
| June,                2007      |   |                                 | 62,027        |   |
| July,                2007      |   |                                 | 62,027        |   |
| **Total**                      |   |                                 | **806.355**   |   |
|                           |   |                                 |          |   |
| **Grand                Total** |   |                                 | **1,343,916** |   |

**Estimated      Pass-through Expenses**

**Third      party costs**

----

*ATTACHMENT      3 TO GENERAL SERVICES AGREEMENT *

**«INVNAME»,      **
*[address]      *
**«SITENAME»,      **
*[address]      *
*[if      applicable, add «Research Company» at *
*«RCADD»]      *
*[insert      name of Quintiles entity], *
*[insert      address] *
**[SPONSOR      LEGAL NAME] **

| **PROTOCOL                NUMBER:** |                                                                                                                                                                                                                                                                                                                                                                 |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **PROTOCOL                TITLE:**  |                                                                                                                                                                                                                                                                                                                                                                 |
| **PROTOCOL                DATE:**   |                                                                                                                                                                                                                                                                                                                                                                 |
| **SPONSOR:**                        |                                                                                                                                                                                                                                                                                                                                                                 |
| **PRINCIPAL INVESTIGATOR:**    | «INVNAME»*Note:                If Investigator is not a party to the Agreement, then Investigator                must be                an actual employee of the Institution, and the following language                must be                included after the**Investigator's                name: “an employee of                Institution"* |

**WHEREAS,      **

**NOW      THEREFORE, **

| 1. | Quintiles                    hereby appoints the Site to conduct the Study, and the Site agrees                    to                    ensure that the Site                    and the Site's employees, agents, and staff will conduct the                    Study in                    accordance with the Protocol,                    the terms of this agreement, including the Terms and Conditions                    attached                    as Attachment                    A, the Payment Schedule and Budget attached as Attachment B,                    and any other                    the attachments                    hereto, which all are incorporated by reference herein (the “Agreement”),                    good clinical                    practices, and all applicable laws and regulations. The Site                    hereby                    confirms that it has enough                    time and resources to perform the Study according to the highest                    quality                    standards. |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2. | Payments                    shall be made in accordance with the provisions set forth in                    Attachment B,                    with the last payment                    being made after the Site completes all its obligations hereunder,                    and                    Quintiles has received                    all completed case report forms (“CRFs”) and, if Quintiles requests, all                    other Confidential Information                    as defined in Attachment A, Section 2 (Confidential and Proprietary                    Information). The Site will act as an independent contractor,                    and shall                    not be considered the employee or agent of Quintiles                    or Sponsor. Neither Quintiles nor Sponsor shall be responsible                    for any                    employee benefits,                    pensions, workers' compensation, withholding, or employment-related                    taxes                    as to the Site.                    The Site acknowledges and agrees that Investigator's judgment                    with respect                    to Investigator's advice to and care of each subject is not affected                    by                    the compensation Site receives                    hereunder. The parties agree that the payee designated below                    is the proper                    payee for this                    Agreement, and that payments under this Agreement will be made                    only to the                    following payee (the“Payee”): |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| **PAYEE                  NAME:****Please                  note: This****should                  be a business****name                  and must****match                  the business name used to file for****your                  tax EIN or other****tax                  ID number** | «PayeeName»                                                                                                                                                                                                                                                                                                                                      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **PAYEE                  ADDRESS:****Please                  Note: this****should                  be street****address,                  not a PO****Box**                                                                                                                           | «PayeeAddress»_______________________________________________________«PayeeAddress2»_______________________________________________________ «PayeeCity»,                  «PayeeState» «PayeePostal_Code»_______________________________________________________                               |
| **TAX                  ID NUMBER****[For                  Canada, Insert:****GST                  & PROVINCIAL****TAX                  IF APPLICABLE]**                                                                                                                           | THE                  TAX ID MUST EXACTLY MATCH THE PAYEE NAME INDICATED                  ABOVE _______________________________________________________For                  Canada: GST                  tax number or applicable provincial tax number _______________________________________________________or                  Tax exempt _____________ |

**If      the Payee is in the United States of America (“U.S.”), the Payee's**
**9      Digit**
**      Tax **
**Identification      Number and SSN/EIN designation will be required before any payments can**
**be      made under this Agreement.**

**Site      will have thirty (30) days from the receipt of final payment to dispute any      payment **
**discrepancies      during the course of the Study.**

**Investigator      **
**acknowledges      that if Investigator is not the Payee, Quintiles will not pay Investigator      even**
**if      the Payee fails to reimburse Investigator.**

| 3. | This                Agreement will become effective on the date on which it is last signed                by                the parties and shall                continue until completion or until terminated in accordance with                the                provision in Attachment A.                In the event of a conflict between the Protocol and this Agreement,                the                terms of the Agreement will govern. |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4. | *[INSERT                ANY SPECIAL COUNTRY REQUIREMENTS, IF                APPLICABLE]* |
|----|------------------------------------------------------------------------------------------|

*For      Sites in the European Union, the following language must be included due to      Data      Privacy *
*laws      and regulations: *

----

*For      Sites in the U.S. insert the following provision: *

**ACKNOWLEDGED      AND AGREED BY **
***[Insert      legal name of Quintiles entity]***

| **By:**                                                                                                                                           |   |   |   |
|---------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|--------|
| **Title:**                                                                                                                                        |   |   |   |
| **Date:**                                                                                                                                         |   |   |   |
|                                                                                                                                              |   |   |   |
| **ACKNOWLEDGED                AND AGREED BY THE PRINCIPAL INVESTIGATOR:**                                                                         |
|                                                                                                                                              |   |   |
| **«INVNAME»**                                                                                                                           |   |   |
| **Date:**                                                                                                                                         |   |   |   |
|                                                                                                                                              |   |   |   |
| **ACKNOWLEDGED                AND AGREED BY***[Insert                legal name of Institution],***if                applicable:**                |
|                                                                                                                                              |   |   |
| **By:**                                                                                                                                           |   |   |   |
| **Title                (must be authorized to sign on Institution's behalf):**___________________                                                 |
| **Date:**                                                                                                                                         |   |   |   |
|                                                                                                                                              |   |   |   |
| **ACKNOWLEDGED                AND AGREED BY***[Insert                legal name of Research Company],***if                 **applicable:**** |
|                                                                                                                                              |   |   |
| **By:**                                                                                                                                           |   |   |   |
| **Title                (must be authorized to sign on Research Company's behalf):**___________________                                            |
| **Date:**                                                                                                                                         |   |   |   |

----

**ATTACHMENT      A **

**TERMS      AND CONDITIONS**

**1)**
**Conduct      of the Study. **

**2)**
**Confidential      and Proprietary Information. **

**3)**
**Publication.      **

----

**4)**
**Inspection      and Debarment. **

**5)**
**Termination.      **

**6)**
**Claims      and Disclaimers. **
**Quintiles      expressly disclaims any liability in connection with the Investigational      Product, including any liability for any product claim arising out of a      condition caused by or allegedly caused by the administration of such product      except to the extent that such liability is caused by the negligence, willful      misconduct or breach of this Agreement by Quintiles. **

----

**7)**
**Financial      Disclosure. **

**8)**
**Shipping      of Dangerous Goods and Infectious Materials. **

**9)**
**Additional      Requirements for Medical Device Studies. **

**10)**
**Additional      Contractual Provisions. **

----

**Attachment      4 **

**Certificate      of Insurance**

----

*Secure      Enterprises Pty Ltd as Trustees for the Strathearn Unit Trust*

*ACN      060 973 908      ABN 94 695 040      625*

*AFSL      229831*

***CERTIFICATE      OF CURRENCY***

**CLASS      OF INSURANCE:**

**INSURED:**

|   | a) | any                director or partner of the Insured whilst acting in their respective                capacities for the Insured; |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------|

|   | b) | any                employee of the Insured including Medical Persons but only whilst                acting                within the scope of their duties; |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | c) | any                past employee who acted for the Insured and who agrees to be bound                by the                terms of this policy; |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------|

|   | d) | any                sub contractor doctor consultant physician hospital or contract research                organization or nurse who will be performing work for the Insured                in                respect of a Trial covered by this                Policy; |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | e) | any                Ethics Committee or its members that has approved a Trial which is                the                subject of this Policy; |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------|

**SCOPE      OF COVER**

| **LIMIT                OF INDEMNITY:**  | AUD$5,000,000                any one claim and in the aggregate |
|-----------------------------------------|-----------------------------------------------------------------|
|                                    |                                                            |
| **EXCESS:**                             | AUD$25,000                each and every claim                  |
|                                    |                                                            |
| **PERIOD                OF INSURANCE:** |                                                            |

| From | : | 23rd                Nov 2005 |
|------|---|------------------------------|
| To   | : | 23rd                Nov 2006 |

|   | Ÿ                  With effect from 14th August 2006 you cover is endorsed                  to include the following                  changes. |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------|

|   | /s/                STRATHEARN INSURANCE BROKERS  |
|--------|-------------------------------------------------------|
|   | **STRATHEARN                INSURANCE BROKERS**  |

----

*Secure      Enterprises Pty Ltd as Trustees for the Strathearn Unit Trust*

*ACN      060 973 908      ABN 94 695 040      625*

*AFSL      229831*

**ENDORSEMENT      ATTACHING TO AND FORMING PART OF THIS POLICY.**

**LEGAL      LIABILITY EXTENSION**

| **TERRITORIAL                LIMITS:** | Worldwide                excluding U.S.A and/or Canada |
|----------------------------------------|--------------------------------------------------------|

**RETROACTIVE      DATE:**

**INSURERS:**

| **Signed                by and on behalf of Strathearn Insurance Brokers** |                                            |
|----------------------------------------------------------------------------|-------------------------------------------------|
|                                                                       |                                            |
|                                                                       | /s/                STRATHEARN INSURANCE BROKERS |
| **Dated:**                27-10-06                                         | **STRATHEARN                INSURANCE BROKERS** |

----

----

| Elkington Bishop Molineaux                     | Suite                4, 651 Victoria Street,   | Telephone | :  | (03)                9425 1890 |
|----------------------------------------------------------|------------------------------------------------|-----------|---------|-------------------------------|
| Insurance                Brokers Pty Ltd                 |  Abbotsford,                Victoria 3067 | Facsimile | :  | (03)                9425 1899 |
| AFS                Licence No. 246986 ABN 31 009 179 640 |                                           | Email     | :  | ebm@ebminsurance.com.au       |
|                                                     |                                           | Website   | :  | www.ebminsurance.com.au       |

| Ms                K Rowe                   | **TAX                INVOICE                      I0537953** |
|--------------------------------------------|--------------------------------------------------------------------------------------------|
| Prana                Biotechnology Limited |                                                                                       |
| Level                2                     |                                                                                       |
| 369                Royal Parade            |                                                                                       |
| PARKVILLE                VIC 3052          |                                                                                       |

| **Invoice                Date**    | :       | 07.04.2006                               | **Premium**                           | 2,000.00                  |
|------------------------------------|---------|------------------------------------------|---------------------------------------|---------------------------|
|                               |    |                                     |                                  |                      |
| **Our                Reference**   | :       | EBM                MEL P0485 0094642/006 | **Stamp                Duty**         | 220.00                    |
|                               |    |                                     |                                  |                      |
| **Invoice                No**      | :       | I0537953                                 |                                  |                      |
|                               |    |                                     |                                  |                      |
| **Class**                          | :       | Broadform                Liability       |                                  |                      |
|                               |    |                                     | **Broker                Fee**         | 50.00                     |
| **Placement****with/by**           | :       | CGU                INSURANCE             |                                  |                      |
|                               |    |                                     | **SubTotal                Excl. GST** | 2,270.00                  |
| **Policy                No ** | :  | 10M1091762                          | **GST                Total**          | 205.00                    |
|                               |    |                                     |                                  |                      |
| **Period**                         | :       | 30.04.2006                to 30.04.2007  | **Total                Amount**       | $                2,475.00 |

**Your      account is managed by:**

| Gino                Renzella | ginor@ebminsurance.com.au  |
|------------------------------|----------------------------|
| Kylie                Allen   | kyliea@ebminsurance.com.au |

**TRANSACTION      DESCRIPTION**

| INSURED: Prana                Biotechnology Limited |       |
|----------------------------------------------------------|------------|
|                                                     |       |
| BRIEF                DESCRIPTION:                        | **[SEAL]** |
| Public                Liability $20,000,000              |       |

|   | 1. | We                are confirming your instructions or inviting Renewal and advising                cover                has been arranged. To ensure continuity of cover, please forward                your                remittance within 14 days. |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2. | The                Insured has a legal obligation to reveal to the Insures any material                fact                which might affect their judgement in acceptance of the insurance                and/or                assessing the premium. Failure to do so could void any contract from                inception. Claims must be notified immediately as late notification                may                cause prejudice in some instances. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **Please                        return this with your remittance to:** | **Our                        Ref**     | :                                       | EBM MEL P0485 0094642/006                                                        |
|------------------------------------------------------------------------|----------------------------------------|-----------------------------------------|-------------------------------------------------------------------------------------------------|
| EBM                        Insurance Brokers                           | **Invoice                        No**  | :                                       | I0537953                                                                                        |
| Suite                        4, 651 Victoria Street                    | **Client                        Name** | :                                       | Prana                        Biotechnology Limited                                              |
| ABBOTSFORD                        VIC 3067                             | **Contact**                            | :                                       | Gino                        Renzella                                                            |
|                                                                   |  Biller Code:Reference:      |  **13581****23152204850053795368** | **Brief                            Description** **Total                          Amount** | : $ | Liab                        $20,000,000 2006/07     2,475.00 |

**Please      see overleaf for payment options.**

----

**COVER      SUMMARY **

| **CLIENT**                                 |   | **PLACEMENT                WITH/BY** | 07.04.06 |
|--------------------------------------------|--------|--------------------------------------|----------|
| Ms                K Rowe                   |   | CGU                Insurance Limited |     |
| Prana                Biotechnology Limited |   | PO                Box 390D           |     |
| Level                2                     |   | MELBOURNE                VIC 3001    |     |
| 369                Royal Parade            |   |                                 |     |
| PARKVILLE                VIC 3052          |   |                                 |     |

| **Your                account is managed by:** |                       |
|------------------------------------------------|----------------------------|
| Gino                Renzella                   | ginor@ebminsurance.com.au  |
| Kylie                Allen                     | kyliea@ebminsurance.com.au |

| **CLASS                OF RISK**      |   | **PERIOD                OF INSURANCE** |
|---------------------------------------|--------|----------------------------------------|
| Broadform                Liability    |   | From:                                  | 4.00                pm on 30th April 2006 |
|                                  |   | To                :                    | 4.00                pm on 30th April 2007 |
| Policy                No : 10M1091762 |   | Our                Ref :               | EBM                MEL P0485 0094642/006 |

| **COVER                SUMMARY** | This                summary is not a policy document and is only an outline of the cover.                The                terms conditions and limitations of the Insurer’s policy shall prevail at                all times. |
|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| INSURED | : | Prana                Biotechnology Limited |
|---------|---|--------------------------------------------|

----

| INTEREST                INSURED | :      | The                Insurer will indemnify you against:                                                                                                                                                                                |
|---------------------------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                            |   |                                                                                                                                                                                                                                  |
|                            |   | 1.                Public Liability; or                                                                                                                                                                                                |
|                            |   | 2.                Products Liability;                                                                                                                                                                                                 |
|                            |   | if                shown in the Schedule as an insured item.                                                                                                                                                                           |
|                            |   |                                                                                                                                                                                                                                  |
| DEFINITIONS                     | :      | PUBLIC                LIABILITY means:                                                                                                                                                                                                |
|                            |   | Your                legal liability to pay damages for an Occurrence (and for consequential                loss caused by the Occurrence), in the course of Your Business, but                excludes products Liability.            |
|                            |   |                                                                                                                                                                                                                                  |
|                            |   | PRODUCTS                LIABILITY means:                                                                                                                                                                                              |
|                            |   | Your                legal liability to pay damages for an Occurrence (and for consequential                loss caused by the Occurrence), caused by an Unknown Defect in Your                Products, but excludes Public Liability |
|                            |   |                                                                                                                                                                                                                                  |
|                            |   | OCCURRENCE                means:                                                                                                                                                                                                      |
|                            |   | Personal                Injury or Damage to Property that:                                                                                                                                                                            |
|                            |   |                                                                                                                                                                                                                                  |
|                            |   | 1. is                neither intended nor expected from the standpoint of a reasonable                person                in your position:                                                                                    |
|                            |   |                                                                                                                                                                                                                                  |
|                            |   | 2. is                caused by an Event; and                                                                                                                                                                                     |
|                            |   |                                                                                                                                                                                                                                  |
|                            |   | 3. occurs:                                                                                                                                                                                                                       |
|                            |   | (a)                within the Geographical Limits                                                                                                                                                                                     |
|                            |   | (b)                during the Period of Insurance                                                                                                                                                                                     |

----

| **COVER                SUMMARY** | Page                No. 2 | Prana                Biotechnology Limited |
|----------------------------------|---------------------------|--------------------------------------------|
|                             |                      | (EBM                MEL P0485 0094642/006) |

| GEOGRAPHICAL                LIMITS | :      | Worldwide                excluding the United States of America and Canada and any state or                territory incorporated in, or administered by, or from, either USA                or                Canada.                                                                                |
|------------------------------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                               |   |                                                                                                                                                                                                                                                                                                  |
| BUSINESS                           | :      | A) Testing                and Marketing a cure for Alzheimers and similar age related                diseases                                                                                                                                                                                    |
|                               |   | B) Property                owners and/or occupiers                                                                                                                                                                                                                                               |
|                               |   |                                                                                                                                                                                                                                                                                                  |
| LIMITS                OF LIABILITY | :      | (a) Public                Liability $20,000,000 any one occurrence                                                                                                                                                                                                                               |
|                               |   | (b) Products                Liability NOT INSURED                                                                                                                                                                                                                                                |
|                               |   |                                                                                                                                                                                                                                                                                                  |
| EXCESS                             | :      | $500                each Occurrence for Property Damage Claims                                                                                                                                                                                                                                        |
|                               |   |                                                                                                                                                                                                                                                                                                  |
| ENDORSEMENT                        | :      | We                will not indemnify you against any liability in connection with any                events                or business activities other than as office occupiers and office                administration at and from the premises situated at the 4 listed                locations. |
|                               |   |                                                                                                                                                                                                                                                                                                  |
| MAJOR                EXCLUSIONS    | :      | Employer’s                Liability (Workers’ Compensation or accident compensation legislation or                any industrial award, agreement or determination)                                                                                                                       |
|                               |   | Discrimination                and harassment                                                                                                                                                                                                                                                          |
|                               |   | Assault                and battery                                                                                                                                                                                                                                                                    |
|                               |   | Waiver                of rights                                                                                                                                                                                                                                                                       |
|                               |   | Contractual                Liability                                                                                                                                                                                                                                                                  |
|                               |   | Intentionally                or recklessly caused injury or damage                                                                                                                                                                                                                                    |
|                               |   | Faulty                Workmanship                                                                                                                                                                                                                                                                     |
|                               |   | Product                recall or repair                                                                                                                                                                                                                                                               |
|                               |   | Reinstatement,                repair or replacement of your products                                                                                                                                                                                                                                  |
|                               |   | Loss                of use of Property from delay in or lack of performance by you or                inadequacy of your products                                                                                                                                                                      |
|                               |   | Aircraft                products                                                                                                                                                                                                                                                                      |
|                               |   | Watercraft                exceeding 8 metres, Hovercraft and Aircraft and areas used for Aircraft                Vehicles requiring registration, other than as a “Working                Tool”                                                                                           |
|                               |   | Earthquake,                civil commotion and the like Pollution                                                                                                                                                                                                                                     |
|                               |   | Asbestos                                                                                                                                                                                                                                                                                              |
|                               |   | Building                and demolition (other than for buildings owned or occupied by you                where                the total cost of alterations does not exceed $ 1,000)                                                                                                                  |
|                               |   | Vibration                or removal or weakening of, or interference with, support to land,                buildings or any other property of support                                                                                                                                                 |
|                               |   | Treatment,                design and professional risks                                                                                                                                                                                                                                               |
|                               |   | Medical/Clinical                testing                                                                                                                                                                                                                                                               |
|                               |   | Libel                and slander made prior to commencement of this insurance, or made                knowing                it’s falsity or related to publishing, advertising, broadcasting or                telecasting activities                                                          |
|                               |   | Fines                and punitive damages                                                                                                                                                                                                                                                             |
|                               |   | Foreign                non-admitted cover                                                                                                                                                                                                                                                             |
|                               |   | Vehicle                mounted cranes                                                                                                                                                                                                                                                                 |

----

| **COVER                SUMMARY** | Page                No. 3 | Prana                Biotechnology Limited(EBM                MEL P0485 0094642/006) |
|----------------------------------|---------------------------|--------------------------------------------------------------------------------------|

|   | Radioactive                contaminationElectronic                date recognitionWar                Terrorism |   |
|--------|----------------------------------------------------------------------------------------------------------------|--------|

| INSURER                                                | POLICY                NUMBER | PROPORTION |
|--------------------------------------------------------|------------------------------|------------|
|                                                   |                         |       |
| CGU                Insurance Limited                   | 10M1091762                   | 100.0000%  |
| A.B.N.                27 004 478 371                   |                         |       |
| CGU                Centre, Level 5, 485 LaTrobe Street |                         |       |
| MELBOURNE                VIC 3000                      |                         |       |

----